People who switched to the experimental daily GLP-1 pill orforglipron were able to maintain their weight loss after stopping ...

The use of GLP-1 drugs to treat obesity has cause awareness of the complex medical condition to surge. But the cost of ...

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

Although still in Phase I, Wave Life Sciences’ injectable RNA weight loss treatment achieved results that impressed analysts, ...

“Early intervention would be lifestyle change, and that can be extremely helpful, especially in younger adolescents who are ...

GLP-1 receptor agonists have captured global attention for their ability to drive weight loss and improve metabolic health.

Congress has the power to make obesity treatment and weight management accessible to the communities that need it.

In addition, the obesity drug also improved knee pain in participants, Eli Lilly noted. ・Seven additional Phase 3 trials for ...

Although the injectable forms of the popular GLP-1 drugs are more effective, the pills under development are both easier to ...

Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or Zepbound largely maintained their weight loss for up to a year.

Beneficial pediatric obesity treatment response was associated with a reduced risk of obesity-related events in young adults, a nationwide prospective cohort study in Sweden showed. Compared with poor ...